Technical Analysis for URGN - UroGen Pharma Ltd.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Up | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Narrow Range Bar | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| NR7 | Range Contraction | -1.79% | |
| NR7-2 | Range Contraction | -1.79% | |
| Narrow Range Bar | Range Contraction | -1.79% | |
| Wide Bands | Range Expansion | -1.79% | |
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | -2.89% | |
| NR7 | Range Contraction | -2.89% | |
| Inside Day | Range Contraction | -2.89% |
| Alert | Time |
|---|---|
| Down 2 % | about 10 hours ago |
| Fell Below Previous Day's Low | about 10 hours ago |
| Down 1% | about 10 hours ago |
| 10 DMA Resistance | about 11 hours ago |
| 60 Minute Opening Range Breakdown | 3 days ago |
Get this analysis on your stocks daily!
- Earnings date: 08/08/2024
UroGen Pharma Ltd. Description
UroGen Pharma Ltd. (UroGen) is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC). Its other clinical-stage drug candidate includes Vesimune and BotuGel. Vesimune is a formulation of the toll-like receptor7 (TLR7) agonist Imiquimod for local intravesical delivery for the treatment of Carcinoma In-Situ. BotuGel is an intravesical sustained release formulation of botulinum toxin for Overactive Bladder (OAB) and Interstitial Cystitis (IC). UroGen has developed two platform technologies: RTGel and Immunotherapy.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Immunotherapy Surgery Chemotherapy Antineoplastic Drugs Carcinoma Bladder Cancer Platform Technologies Botulinum Toxin Oab Interstitial Cystitis Overactive Bladder Tlr7 Two Platform Technologies Urinary Bladder
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 24.13 |
| 52 Week Low | 8.69 |
| Average Volume | 664,192 |
| 200-Day Moving Average | 14.57 |
| 50-Day Moving Average | 14.35 |
| 20-Day Moving Average | 15.50 |
| 10-Day Moving Average | 16.85 |
| Average True Range | 1.21 |
| RSI (14) | 55.36 |
| ADX | 23.66 |
| +DI | 25.65 |
| -DI | 20.79 |
| Chandelier Exit (Long, 3 ATRs) | 17.07 |
| Chandelier Exit (Short, 3 ATRs) | 15.93 |
| Upper Bollinger Bands | 19.68 |
| Lower Bollinger Band | 11.32 |
| Percent B (%b) | 0.62 |
| BandWidth | 53.97 |
| MACD Line | 0.85 |
| MACD Signal Line | 0.80 |
| MACD Histogram | 0.047 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 17.34 | ||||
| Resistance 3 (R3) | 17.39 | 17.16 | 17.20 | ||
| Resistance 2 (R2) | 17.16 | 16.94 | 17.13 | 17.15 | |
| Resistance 1 (R1) | 16.82 | 16.80 | 16.70 | 16.77 | 17.10 |
| Pivot Point | 16.58 | 16.58 | 16.52 | 16.56 | 16.58 |
| Support 1 (S1) | 16.24 | 16.36 | 16.13 | 16.19 | 15.86 |
| Support 2 (S2) | 16.01 | 16.23 | 15.98 | 15.81 | |
| Support 3 (S3) | 15.67 | 16.01 | 15.76 | ||
| Support 4 (S4) | 15.62 |
